Man with daughter on the motorcycle
icon-tb-management
TB Management

Risk Groups

Who is at risk for TB?

It is estimated that up to 10% of people infected with M. tuberculosis will develop active TB in their lifetime. About one-quarter of the world’s population has a TB infection. The vast majority have no signs or symptoms of TB disease and are not infectious, although they are at risk of developing active TB disease and becoming infectious.

The WHO recommends systematic latent TB testing for TB risk groups, including (1):

  1. Adults, adolescents, children and infants living with HIV
  2. Children aged ≥ 5 years, adolescents and adults who are contacts of TB patients
  3. Patients initiating anti-TNF treatment, receiving dialysis, preparing for organ, hematological transplantation or have silicosis

The purpose of TB screening is to find cases at an early asymptomatic phase that is easily curable and find latent TB infection (LTBI) among individuals who may benefit from preventive treatment.

  • Biologics
    Treatment with biologic agents, in particular tumor necrosis factor-alpha (TNF-α) inhibitors, has revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. However, patients receiving anti-TNF-α therapy are at increased risk of TB infection.
    Female doctor talking to older male patient
  • Diabetes
    Diabetes is increasingly being recognized as an independent risk factor for TB. Someone with untreated latent TB infection and diabetes is more likely to develop TB disease than someone without diabetes. See how the development of TB in diabetes patients can be prevented by actively testing and treating LTBI.
    District nurse at home visit, patient, Healthcare worker
  • Pediatrics
    Once infected with the TB bacteria, children with vulnerable immune systems are most at risk of progressing to active TB disease. TB is preventable, yet over 1.1 million children become ill with it every year. Find out how we can protect children from TB.
    Latin mother with young girl
  • Female doctor talking to older male patient
    Biologics
  • District nurse at home visit, patient, Healthcare worker
    Diabetes
  • Latin mother with young girl
    Pediatrics
The COVID-19 pandemic is negatively impacting TB testing services
International efforts have succeeded in slowing the COVID-19 pandemic, but responding to COVID-19 has also forced disruption of TB control programs around the globe. Such disruption has reversed a decade of progress against TB, with a recent report released by Stop TB suggesting the potential for an additional 1.4 million tuberculosis deaths by 2025, due to COVID-19-related disruption to TB prevention services (2).
Finding ways to integrate TB and COVID-19 care programs

Dr. Alistair Story, from London’s Find&Treat mobile health service discusses the impact of the COVID-19 pandemic on the service and how the lessons learned through years of running the service has helped it to manage the additional burden of COVID-19.

QuantiFERON-TB Gold Plus tubes
Improve TB screening with QFT-Plus
  • Single patient visit
  • Unaffected by BCG vaccination
  • >94% sensitivity
  • >97% specificity
  • Innovative CD8+ T cell technology
References:
  1. World Health Organization. (2020) WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf
  2. Stop TB Partnership in collaboration with Imperial College, Avenir Health, Johns Hopkins University and USAID. The potential impact of the COVID-19 response on tuberculosis in high-burden countries: a modeling analysis.

QFT-Plus is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection. QFT-Plus is an indirect test for M. tuberculosis infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. QFT-Plus Package Inserts, available in multiple languages, as well as up-to-date licensing information and product-specific disclaimers can be found at www.QuantiFERON.com.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm